Compass says depression drug has long-lasting benefits
Compass Pathways reports positive six-month data for its psilocybin-based depression treatment, fueling market confidence and future filing plans.
Coverage (7)
-
-
-
-
-
-
-
Compass says depression drug has long-lasting benefits STAT · 96d ago broke it first
The brief
- Velocity & Diffusion: Coverage escalated across 6 distinct news outlets with 7 published articles, achieving a live velocity of 4.
- Primary Driver: Compass Pathways reports positive six-month data for its psilocybin-based depression treatment, fueling market confidence and future filing plans.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
Compass Pathways has released results from its second Phase 3 clinical trial involving the investigational drug COMP360. Data indicates that the psilocybin treatment maintained depression-related benefits for participants through a 26-week period.
Coverage from outlets including STAT, Endpoints News, and Business Wire emphasizes the durability and rapid onset of the drug's effects. Financial analysis and market reporting from Moomoo, BTIG, and Psychedelic Alpha highlight positive shifts in company stock performance and the maintenance of a buy rating for the firm.
Attention now shifts to the company's regulatory timeline. Reported plans include a year-end filing with health authorities, with the organization looking toward a potential launch in the first half of 2027.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 93d ago.
Quick answers
What is the duration of the benefits reported?
Clinical trial data confirms that benefits were sustained through 26 weeks.
When does Compass Pathways anticipate a product launch?
The company is targeting a launch in the first half of 2027.
How have analysts responded to the data?
BTIG has maintained a buy rating for Compass Pathways, and shares have gained following the announcement.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
People, places & organizations
Topics
Related trends
U. grad with stage 4 cancer heads to Washington to push for clinical trial access
A university graduate with stage 4 cancer is heading to Washington to advocate for clinical trial access.
VA to run trial of GLP-1 drug to treat alcohol abuse
4 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
Could a Multivitamin Help You Age Better? Study Suggests Yes
9 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
Death of girl in Chinese gene-editing trial kept secret: Report
5 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
First person gets new experimental vaccine for Ebola
The world's first vaccine targeting the Bundibugyo ebolavirus has entered human clinical trials following the first volunteer vaccination.
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.